Safety of short-acting nifedipine in children with severe hypertension

Expert Opinion on Drug Safety

Volumn 2, Issue 2, 2003, Pages 133-139

  Flynn, Joseph T ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

blood pressure (BP); calcium antagonists; children; hypertensive emergency; hypotension; nifedipine; renal disease; stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE;

CHILD; CLINICAL TRIAL; HUMAN; HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; CLINICAL TRIALS; HUMANS; HYPERTENSION; NIFEDIPINE;

EID: 2142808704     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.2.133     Document Type: Review

References (62)

1. FLECKENSTEIN-GRÜN G: Calcium antagonism in vascular smooth muscle cells. Pflügers Arch. (1996) 432(Suppl. 3):R53-R60.
2. TRIGGLE DL: Mechanisms of action of calcium channel antagonists. In: Calcium Antagonists in Clinical Medicine, (2nd edn). Epstein M (Ed.), Hanley & Belfus, Inc., Philadelphia (1998):1-26.
3. SPEDDING M, PAOLETTI R: Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. (1992) 44:363-376.
4. VARADI G, MORI Y, MIKALA G, SCHWARTZ A: Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol. Sci. (1995) 16:43-49.
5. BEAN BP: Pharmacology of calcium channels in cardiac muscle, vascular muscle and neurons. Am. J. Hypertens. (1991) 4:S406-S411.
6. RAM JL, STANDLEY PR, SOWERS JR: Calcium function in vascular smooth muscle. In: Calcium Antagonists in Clinical Medicine. Epstein M (Ed.), Hanley & Belfus, Inc., Philadelphia (1992):29-48.
7. FLECKENSTEIN A: Discovery and mechanism of action specific calciumantagonistic inhibitors of excitation-contraction coupling in the mammalian myocardium. In: Calcium antagonism in heart and smooth muscle: experimental facts and therapeutic prospects. John Wiley, Inc., New York (1983):34-40.
8. NAYLER WG: Classification and tissue selectivity of calcium antagonists. Z. Kardiol. (1990) 79(Suppl. 3):107-111.
9. TOYO-OKA T, NAYLER WG: Third generation calcium entry blockers. Blood Press. (1996) 5:206-208.
10. MURDOCH D, HEEL RC: Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs (1991) 41:478-505.
11. KLEINBLOESEM CH, VAN BRUMMELEN P, VAN DE LINDE JA, VOOGD PJ, BREIMER DD: Nifedipine: kinetics and dynamics in healthy subjects. Clin. Pharmacol. Ther. (1984) 35:742-749.
12. PHYSICIAN'S DESK REFERENCE: Product Information, Pfizer, Inc. Procardia® capsules and Procardia XL® . Thomson Healthcare, Montvale, NJ (2002).
13. FOSTER TS, HAMANN SR, RICHARDS VR, BRYANT PJ, GRAVES DA, MCALLISTER RG: Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol. (1983) 23:161-170.
14. MONCICA I, OH PI, UL QAMAR I et al.: A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch. Dis. Child. (1995) 73:154-156.
15. SILVERSTEIN DM, PALMER JA, BALUARTE HJ, BRAAS C, CONLEY SB, POLINSKY MS: Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr. Transpl. (1999) 3:288-292.
16. KLEINBLOESEM CH, VAN BRUMMELEN P, VAN HARTEN J, DANHOF M, BREIMER DD: Nifedipine: influence of renal function and pharmacokinetic/hemodynamic relationship. Clin. Pharmacol. Ther. (1985) 37:563-574.
17. VAN HARTEN J, BURGGRAFF K, DANHOF M, VAN BRUMMELEN P, BREIMER DD: Negligible sublingual absorption of nifedipine. Lancet (1987) 2:1363-1365.
18. DILMEN U, ÇAGLAR K, SENSES DA, KINIK E: Nifedipine in hypertensive emergencies in children. Am. J. Dis. Child. (1983) 137:1162-1165.
19. LOPEZ-HERCE J, DORAO P, DE LA OLIVIA P, DELGADO MA, MARTINEZ MC, RUZA F: Dosage of nifedipine in hypertensive crises of infants and children. Eur. J. Pediatr. (1989) 149:136-137.
20. ROTH B, HERKENRATH P, KREBBER J, ABU-CHAABAN M: Nifedipine in hypertensive crises of infants and children. Clin. Exp. Hypertens. [A] (1986) 8:871-877.
21. SIEGLER RL, BREWER ED: Effect of sublingual or oral nifedipine in the treatment of hypertension. J. Pediatr. (1988) 112:811-813.
22. EVANS JHC, SHAW NJ, BROCKLEBANK JT: Sublingual nifedipine in acute severe hypertension. Arch. Dis. Child. (1988) 63:975-977.
23. YIU VWY, ORRBINE E, ROSYCHUK R et al.: The use of short-acting nifedipine in acute blood pressure reduction in hospitalized hypertensive children. J. Am. Soc. Nephrol. (2000) 11:A356. Abstract.
24. BLASZAK RT, SAVAGE JA, ELLIS EN: The use of short-acting nifedipine in pediatric patients with hypertension. J. Pediatr. (2001) 139:34-37.
25. EGGER DW, DEMING DD, HAMADA N, PERKIN RM, SAHNEY S: Evaluation of the safety of short acting nifedipine in children with hypertension. Pediatr. Nephrol. (2002) 17:35-40.
26. ADELMAN RD, COPPO R, DILLON MJ: The emergency management of severe hypertension. Pediatr. Nephrol. (2000) 14:422-427.
27. CALVETTA A, MARTINO S, VON VIGIER RO, SCHMIDTKO J, FOSSALI E, BIANCHETTI MG: 'What goes up must immediately come down!' Which indication for short-acting nifedipine in children with arterial hypertension? Pediatr. Nephrol. (2003) 18:1-2.
28. KUMAR P, ARORA P, KHER V et al.: Malignant hypertension in children in India. Nephrol. Dial. Transplant. (1996) 11:1261-1266.
29. BARTOSH SM, ARONSON AJ: Childhood hypertension: an update on etiology, diagnosis, and treatment. Pediatr. Clin. North Am. (1999) 46:235-252.
30. TEMPLE ME, NAHATA MC: Treatment of pediatric hypertension. Pharmacotherapy (2000) 20:140-150.
31. BELSHA CW: Systemic hypertension: management in children and adolescents. Curr. Treat. Opt. Cardiovasc. Med. (2002) 4:351-360.
32. AL EDRESSI M, CAILLE G, DUPUIS C, THEORET Y, PARADIA K: Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine. Liver Transpl. Surg. (1995) 1:383-388.
33. WACHTER RM: Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch. Intern. Med. (1987) 147:556-558.
34. SCHWARTZ M, NASCHITZ JE, YESHURUN D, SHARF B: Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose. Arch. Intern. Med. (1990) 150:686-687.
35. REHMAN F, MANSOOR GA, WHITEWB: 'Inappropriate' physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am. J. Hypertens. (1996) 9:1035-1039.
36. GROSSMAN E, MESSERLI FH, GRODZICKI T, KOWEY P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? J. Am. Med. Assoc. (1996) 276:1328-1331.
37. MESSERLI FH: The use of sublingual nifedipine. A continuing concern. Arch. Intern. Med. (1999) 159:2259-2260.
38. NO AUTHORS LISTED: Safety briefs. Institute for Safe Medication Practices, ISMP Medication Safety Alert! (2000) 5(1):1-2.
39. FURBERG CD, PSATY BM, MEYER JF: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation (1995) 92:1326-1331.
40. PSATY BM, HECKBERT SR, KOEPSELLTD et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. J. Am. Med. Assoc. (1995) 274:620-625.
41. BERHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). J. Am. Med. Assoc. (1996) 276:785-791.
42. AD HOC SUBCOMMITTEE OF THE LIAISON COMMITTEE OF THE WORLD HEALTH ORGANIZATION AND THE INTERNATIONAL SOCIETY OF HYPERTENSION: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J. Hypertens. (1997) 15:105-115.
43. LINDBERG G, BINGEFORS K, RANSTAM J, RANSTAM L, MELANDER A: Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. Br. Med. J. (1998) 316:741-745.
44. DUNN NR, FREEMANTLE SN, MANN RD: Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br. J. Clin. Pharmacol. (1999) 48:230-233.
45. ALDERMAN MH, COHEN M, ROQUÉ R, MADHAVAN S: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet (1997) 349:549-598.
46. KLONER RA, VETROVEC GW, MATERSON BJ, LEVENSTEIN M: Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am. J. Cardiol. (1998) 81:163-169.
47. GILLMAN MW, ROSS-DEGNAN D, MCLAUGHLIN TJ et al.: Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction. J. Am. Geriatr. Soc. (1999) 47:512-517.
48. GAUTHIER B, TRACHTMAN H: Short-acting nifedipine. Pediatr. Nephrol. (1997) 11:786-787.
49. SINAIKO AR, DANIELS SR: The use of short-acting nifedipine in children with hypertension: another example of the need for comprehensive drug testing in children. J. Pediatr. (2001) 139:7-9.
50. SASAKI R, HIROTA K, MASUDA A: Nifedipine-induced transient cerebral ischemia in a child with Cockayne syndrome. Anaesthesia (1997) 52:1236.
51. TRUTTMANN AC, AEHNDERSCHLAPBACH S, BIANCHETTI MG: A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises. Pediatr. Nephrol. (1998) 12:259.
52. LEONARD MB, KASNER SE, FELDMAN HI, SCHULMAN SL: Adverse neurologic events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. Pediatr. Emerg. Care (2001) 17:435-437.
53. CASTANEDA M, WORONIECKI R, FLYNN J: Ventricular arrhythmia in an adolescent after short-acting nifedipine administration. Pediatr. Nephrol. (2001) 16(8):C172. Abstract.
54. FLYNN JT: Pediatric use of antihypertensive medications: much more to learn. Curr. Ther. Res. Clin. Exp. (2001) 62:314-328.
55. ADCOCK KG, WILSON JT: Nifedipine labeling illustrates the pediatric dilemma for off-patent drugs. Pediatrics (2002) 109:319-321.
56. ROSEN WJ, JOHNSON CE: Evaluation of five procedures for measuring nonstandard doses of nifedipine liquid. Am. J. Hosp. Pharm. (1989) 46:2313-2317.
57. WILSON DJ, WALLIN JD, VLACHAKIS ND et al.: Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am. J. Med. (1983) 75:95-102.
58. FLYNN JT, MOTTES TA, BROPHY PB, KERSHAW DB, SMOYER WE, BUNCHMAN TE: Intravenous nicardipine for treatment of severe hypertension in children. J. Pediatr. (2001) 139:38-43.
59. STRIFE CF, QUINLAN M, WALDO FB et al.: Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics (1986) 78:861-865.
60. MIRKIN BL, NEWMAN TJ: Efficacy of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics (1985) 75:1091-1100.
61. SARAGOÇA MA, PORTELA JE, PLAVNIK F, VENTURA RP, LOTAIF L, RAMOS OL: Isradipine in the treatment of hypertensive crisis in ambulatory patients. J. Cardiovasc. Pharmacol. (1992) 19(Suppl. 3):S76-S78.
62. FLYNN JT, WARNICK SJ: Isradipine treatment of hypertension in children: a single-center experience. Pediatr. Nephrol. (2002) 17:748-753.